Polar Asset Management Partners Inc. Buys New Position in Simulations Plus, Inc. $SLP

Polar Asset Management Partners Inc. bought a new stake in Simulations Plus, Inc. (NASDAQ:SLP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 127,874 shares of the technology company’s stock, valued at approximately $2,341,000.

Other institutional investors also recently added to or reduced their stakes in the company. Meros Investment Management LP acquired a new position in shares of Simulations Plus during the second quarter worth approximately $2,384,493,000. Hsbc Holdings PLC acquired a new stake in shares of Simulations Plus in the second quarter worth $520,000. Canada Pension Plan Investment Board acquired a new stake in shares of Simulations Plus in the second quarter worth $223,000. Legal & General Group Plc bought a new position in Simulations Plus during the second quarter worth $89,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Simulations Plus during the second quarter worth $943,000. 78.08% of the stock is owned by institutional investors.

Simulations Plus Price Performance

Shares of SLP stock opened at $18.39 on Wednesday. The stock has a market cap of $372.03 million, a P/E ratio of 45.98 and a beta of 1.32. Simulations Plus, Inc. has a one year low of $11.09 and a one year high of $21.01. The stock has a fifty day moving average price of $18.30 and a 200 day moving average price of $15.34.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.07. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%. The firm had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million.

Analyst Upgrades and Downgrades

SLP has been the topic of several research analyst reports. Wall Street Zen lowered shares of Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. William Blair lowered shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Craig Hallum cut shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 target price for the company. in a research note on Thursday, June 18th. Finally, Weiss Ratings raised Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. Seven investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $17.25.

Insider Buying and Selling at Simulations Plus

In other news, Director Walter S. Woltosz sold 4,177 shares of Simulations Plus stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the sale, the director directly owned 3,202,131 shares in the company, valued at approximately $59,047,295.64. The trade was a 0.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.10% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.